GSK

2,055

+0.1%↑

STJ

1,298.5

-2.22%↓

HIK

1,212

+0.41%↑

GSK

2,055

+0.1%↑

STJ

1,298.5

-2.22%↓

HIK

1,212

+0.41%↑

GSK

2,055

+0.1%↑

STJ

1,298.5

-2.22%↓

HIK

1,212

+0.41%↑

GSK

2,055

+0.1%↑

STJ

1,298.5

-2.22%↓

HIK

1,212

+0.41%↑

GSK

2,055

+0.1%↑

STJ

1,298.5

-2.22%↓

HIK

1,212

+0.41%↑

Search

AstraZeneca PLC

Aperta

SettoreSettore sanitario

14,404 -1.96

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

14354

Massimo

14706

Metriche Chiave

By Trading Economics

Entrata

-177M

2.4B

Vendite

312M

16B

P/E

Media del settore

29.855

66.845

EPS

1.19

Rendimento da dividendi

1.65

Margine di Profitto

15.199

Dipendenti

96,100

EBITDA

-530M

4.6B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+10.64% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.65%

2.25%

Utili prossimi

29 apr 2026

Prossima data del Dividendo

23 mar 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-282B

302B

Apertura precedente

14405.96

Chiusura precedente

14404

Notizie sul Sentiment di mercato

By Acuity

37%

63%

106 / 351 Classifica in Healthcare

AstraZeneca PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 feb 2026, 11:41 UTC

Utili

AstraZeneca Reiterates $80 Billion Revenue Goal for 2030 -- Update

10 feb 2026, 07:39 UTC

Utili

AstraZeneca Forecasts Continued Growth on Pipeline Strength

10 feb 2026, 14:41 UTC

Utili
Azioni calde

BP, Ferrari, TSMC: Global Earnings in Focus -- WSJ

10 feb 2026, 13:18 UTC

Utili
Azioni calde

Ferrari, BP, TSMC: Global Earnings in Focus -- WSJ

10 feb 2026, 12:01 UTC

Utili

AstraZeneca 4Q Adj EPS $2.12 >AZN

10 feb 2026, 12:01 UTC

Utili

AstraZeneca 4Q Rev $15.5B >AZN

10 feb 2026, 12:01 UTC

Utili

AstraZeneca 4Q EPS $1.50 >AZN

10 feb 2026, 10:27 UTC

Utili
Azioni calde

BP, Kering, Barclays: Earnings Around the World in Focus -- WSJ

10 feb 2026, 07:45 UTC

Discorsi di Mercato
Utili

AstraZeneca's Revenue Guidance Beats Expectations -- Market Talk

10 feb 2026, 07:08 UTC

Utili

AstraZeneca: 2026 Core EPS Expected to Increase by Low Double-Digit Percentage

10 feb 2026, 07:07 UTC

Utili

AstraZeneca: 2026 Total Revenue Expected to Increase by Mid-To-High Single-Digit Percentage

10 feb 2026, 07:05 UTC

Utili

Analysts Saw AstraZeneca 4Q Adj EPS at $2.11

10 feb 2026, 07:04 UTC

Utili

Analysts Saw AstraZeneca 4Q Revenue at $15.505B

10 feb 2026, 07:02 UTC

Utili

AstraZeneca 4Q Adj EPS $2.12

10 feb 2026, 07:02 UTC

Utili

AstraZeneca 4Q Rev $15.5B

10 feb 2026, 07:00 UTC

Utili

AstraZeneca Issues 2026 View

10 feb 2026, 07:00 UTC

Utili

AstraZeneca PLC 4Q Adj EPS $2.12

10 feb 2026, 07:00 UTC

Utili

AstraZeneca PLC 4Q Pretax Pft $2.63B

10 feb 2026, 07:00 UTC

Utili

AstraZeneca PLC 4Q Rev $15.5B

10 feb 2026, 07:00 UTC

Utili

AstraZeneca PLC 4Q Oper Pft $2.98B

10 feb 2026, 07:00 UTC

Utili

AstraZeneca PLC 4Q Net Pft $2.33B

10 feb 2026, 07:00 UTC

Utili

AstraZeneca PLC 4Q EPS $1.49

9 feb 2026, 08:56 UTC

Utili

AstraZeneca's Weight-Loss Drug Strategy in Focus -- Earnings Preview

16 gen 2026, 17:03 UTC

Discorsi di Mercato

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

12 gen 2026, 10:19 UTC

Azioni calde

Stocks to Watch Monday: Capital One, Amex, Citi, Walmart -- WSJ

30 dic 2025, 08:45 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

A GSK, AstraZeneca Merger Could Be a Possibility -- Market Talk

11 nov 2025, 13:38 UTC

Discorsi di Mercato
Utili

AstraZeneca Shares Hit Record High After Earnings Beat, U.S. Price Deal -- Market Talk

6 nov 2025, 12:07 UTC

Discorsi di Mercato

AstraZeneca Should Continue to Outpace Peers, Stick to Margin Goal -- Market Talk

6 nov 2025, 12:02 UTC

Utili

AstraZeneca Sees FY25 Core EPS Increasing by Low Double-Digit Percentage >AZN.LN

6 nov 2025, 12:02 UTC

Utili

AstraZeneca Sees FY25 Total Rev Increasing by High Single-Digit Percentage >AZN.LN

Confronto tra pari

Modifica del prezzo

AstraZeneca PLC Previsione

Obiettivo di Prezzo

By TipRanks

10.64% in crescita

Previsioni per 12 mesi

Media 15,977.95 GBX  10.64%

Alto 18,400 GBX

Basso 11,300 GBX

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per AstraZeneca PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

15 ratings

12

Acquista

2

Mantieni

1

Vendi

Sentiment

By Acuity

106 / 351 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
help-icon Live chat